CD137 Antibodies Clinical Trials & Market Opportunity - Yahoo Finance
CD137 antibodies show promise in cancer immunotherapy by stimulating T cells, with no licensed drugs yet but over 80 in clinical trials, mainly in phase 2. Major companies like BioNTech and Genmab are developing these therapies, which could enhance existing treatments and expand to other diseases. The market potential is significant, with challenges in dosing and resistance needing resolution.
Reference News
CD137 antibodies show promise in cancer immunotherapy by stimulating T cells, with no licensed drugs yet but over 80 in clinical trials, mainly in phase 2. Major companies like BioNTech and Genmab are developing these therapies, which could enhance existing treatments and expand to other diseases. The market potential is significant, with challenges in dosing and resistance needing resolution.